Business
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc. (Nasdaq:FTHM) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg ...
About this update from Fathom Holdings Inc.
[{"type":"text","content":"ORLANDO, FLORIDA / ACCESS Newswire / July 3, 2025 / RedChip Companies will air interviews with Fathom Holdings, Inc. (Nasdaq:FTHM) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, July 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.","length":378,"tagName":"p"},{"type":"text","content":"Access the interviews in their entirety at:","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"FTHM: https://www.redchip.com/assets/access/fthm_access","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"FBLG: https://www.redchip.com/assets/access/fblg_access","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":110,"olType":false},{"type":"text","content":"In an exclusive interview, Marco Fregenal, CEO of Fathom Holdings, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's disruptive approach to real estate services through its proprietary, technology-driven platform. Fregenal highlights Fathom's flat-fee commission model, which empowers agents to retain more of their earnings while enabling industry-leading retention and rapid national expansion. With operations in 43 states and a network of over 14,700 agents, Fathom is scaling efficiently through its virtual model, integrated ancillary services, and strategic acquisitions, including the recent addition of My Home Group. He also addresses Fathom's innovative Bitcoin strategy and strong financial performance, including a 32% year-over-year revenue increase in Q1 2025, positioning the Company to capture additional market share amid an improving housing market.","length":923,"tagName":"p"},{"type":"text","content":"Pete O'Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to spotlight the company's pioneering work in fibroblast-based cell therapies. O'Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company's robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia late...